We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis, Roche Gain European Clearances for Competing Indications
Novartis, Roche Gain European Clearances for Competing Indications
Novartis’ Kesimpta and Roche’s Evrysdi both received marketing authorizations from the European Commission (EC) Tuesday, setting the stage for new competing indications between the two companies.